Subcutaneous vs. Intramuscular Testosterone

ClinicalTrials.gov ID: NCT03091348

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT03091348. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 12:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Subcutaneous Testosterone Therapy in Men Compared to Intramuscular Testosterone Therapy in Men

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

In this randomized, cross-over study 20 subjects who are undergoing testosterone (T) therapy for the treatment of T deficiency will receive both subcutaneous testosterone therapy and intramuscular testosterone therapy. One group will receive a SQ injection followed by an IM injection and one group will receive an IM injection followed by a SQ injection. The primary objective of this study is to measure testosterone concentration in men after these two treatment routes and determine if there are any significant differences due to modes of administration. Endpoints will include total serum testosterone and calculated free testosterone. A questionnaire will also be administered to assess overall patient experience with each route of administration.

Study identification

NCT ID: NCT03091348
Recruitment status: Completed
Study type: Interventional
Phase: Phase 4
Lead sponsor: Men's Health Boston; Other
Enrollment: 4 participants

Conditions and interventions

Conditions

Interventions

Testosterone Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 90 Years
Sex: Male
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 29, 2017 (Actual)
Primary completion: Nov 21, 2017 (Actual)
Completion: Jan 2, 2018 (Actual)
Last update posted: Oct 8, 2019

2017 – 2018

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Men's Health Boston	Chestnut Hill	Massachusetts	02467	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03091348, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 8, 2019 · Synced Nov 13, 2026